

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.8237 - JOHNSON & JOHNSON / ABBOTT MEDICAL OPTICS

SECTION 1.2

Description of the concentration

Johnson & Johnson (“**J&J**”) has submitted a notification of a proposed concentration pursuant to Article 4(2) of the EC Merger Regulation, through which J&J proposes to acquire within the meaning of Article 3(1)(b) of the EC Merger Regulation sole control over Abbott Medical Optics Inc. (“**AMO**”), by way of purchase of shares.

The activities of the undertakings concerned by the notified transaction are as follows:

- J&J is the ultimate parent company of a global group of companies whose activities are divided into three business segments: (i) Consumer Healthcare, (ii) Pharmaceuticals, and (iii) Medical Devices. The activities that will be acquired in the notified concentration primarily fall within the Medical Devices segment and to a much more limited extent within the Consumer Healthcare segment.
- AMO is a global provider of ophthalmic products to health-care providers and patients in three business categories: (i) Cataract Surgery, (ii) Refractive Surgery and (iii) Consumer Eye Health. AMO is a wholly-owned subsidiary of Abbott Laboratories, a global health care company headquartered in Illinois (USA) and listed on the New York, Chicago, London, and Swiss stock exchanges.